Trial · NCT00965757
Results by group102
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 102
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Change From Baseline in Tender Joint Counts and Swollen Joint Counts | T-614 (Double-blind, 1-28 Weeks) and (Extension, 29-52 Weeks) | Baseline: TJC | 12.5 | Standard Deviation 6.5 | joint counts |
| Change From Baseline in Tender Joint Counts and Swollen Joint Counts | Placebo (Double-blind, 1-28 Weeks) | Baseline: TJC | 13.3 | Standard Deviation 8.1 | joint counts |
| Change From Baseline in Tender Joint Counts and Swollen Joint Counts | Placebo/T-614 (Extension, 29-52 Weeks) | Baseline: TJC | 13.8 | Standard Deviation 8.5 | joint counts |
| Change From Baseline in Tender Joint Counts and Swollen Joint Counts | T-614 (Double-blind, 1-28 Weeks) and (Extension, 29-52 Weeks) | Change from baseline at week 24 LOCF: TJC | -7.4 | Standard Deviation 6 | joint counts |
| Change From Baseline in Tender Joint Counts and Swollen Joint Counts | Placebo (Double-blind, 1-28 Weeks) | Change from baseline at week 24 LOCF: TJC | -4.6 | Standard Deviation 7.8 | joint counts |
| Change From Baseline in Tender Joint Counts and Swollen Joint Counts | Placebo/T-614 (Extension, 29-52 Weeks) | Change from baseline at week 24 LOCF: TJC | NA | Standard Deviation NA | joint counts |
| Change From Baseline in Tender Joint Counts and Swollen Joint Counts | T-614 (Double-blind, 1-28 Weeks) and (Extension, 29-52 Weeks) | Change from baseline at week 52 LOCF: TJC | -8.4 | Standard Deviation 6.1 | joint counts |
| Change From Baseline in Tender Joint Counts and Swollen Joint Counts | Placebo (Double-blind, 1-28 Weeks) | Change from baseline at week 52 LOCF: TJC | NA | Standard Deviation NA | joint counts |
| Change From Baseline in Tender Joint Counts and Swollen Joint Counts | Placebo/T-614 (Extension, 29-52 Weeks) | Change from baseline at week 52 LOCF: TJC | -9.9 | Standard Deviation 7.6 | joint counts |
| Change From Baseline in Tender Joint Counts and Swollen Joint Counts | T-614 (Double-blind, 1-28 Weeks) and (Extension, 29-52 Weeks) | Baseline: SJC | 11.5 | Standard Deviation 6.3 | joint counts |
| Change From Baseline in Tender Joint Counts and Swollen Joint Counts | Placebo (Double-blind, 1-28 Weeks) | Baseline: SJC | 11.1 | Standard Deviation 5.7 | joint counts |
| Change From Baseline in Tender Joint Counts and Swollen Joint Counts | Placebo/T-614 (Extension, 29-52 Weeks) | Baseline: SJC | 10.9 | Standard Deviation 5.8 | joint counts |
| Change From Baseline in Tender Joint Counts and Swollen Joint Counts | T-614 (Double-blind, 1-28 Weeks) and (Extension, 29-52 Weeks) | Change from baseline at week 24 LOCF: SJC | -6.5 | Standard Deviation 5.9 | joint counts |
| Change From Baseline in Tender Joint Counts and Swollen Joint Counts | Placebo (Double-blind, 1-28 Weeks) | Change from baseline at week 24 LOCF: SJC | -2.9 | Standard Deviation 6.7 | joint counts |
| Change From Baseline in Tender Joint Counts and Swollen Joint Counts | Placebo/T-614 (Extension, 29-52 Weeks) | Change from baseline at week 24 LOCF: SJC | NA | Standard Deviation NA | joint counts |
| Change From Baseline in Tender Joint Counts and Swollen Joint Counts | T-614 (Double-blind, 1-28 Weeks) and (Extension, 29-52 Weeks) | Change from baseline at week 52 LOCF: SJC | -7.1 | Standard Deviation 6.8 | joint counts |
| Change From Baseline in Tender Joint Counts and Swollen Joint Counts | Placebo (Double-blind, 1-28 Weeks) | Change from baseline at week 52 LOCF: SJC | NA | Standard Deviation NA | joint counts |
| Change From Baseline in Tender Joint Counts and Swollen Joint Counts | Placebo/T-614 (Extension, 29-52 Weeks) | Change from baseline at week 52 LOCF: SJC | -6.3 | Standard Deviation 6.5 | joint counts |
| Change From Baseline in PAP, PtGADA and PyGADA | T-614 (Double-blind, 1-28 Weeks) and (Extension, 29-52 Weeks) | Baseline PAP | 47.5 | Standard Deviation 22.2 | mm |
| Change From Baseline in PAP, PtGADA and PyGADA | Placebo (Double-blind, 1-28 Weeks) | Baseline PAP | 46.4 | Standard Deviation 23.1 | mm |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT00965757/results